Topic resource collection
Approved comparison material connected to this topic.
37 resourcesRead both sides
Primary Receptor Target GPR54 (KISS1R) in GnRH neurons OXTR in uterus, mammary glands, limbic system No receptor overlap. Mutually exclusive binding targets Mechanism of Action Stimulates GnRH release → triggers LH/FSH → drives g…
A 2017 study published in Cell demonstrated that FOXO4-DRI induced selective apoptosis in senescent cells while leaving healthy cells intact. The peptide interfered with the FOXO4-p53 protein interaction that normally prevents da…
A 2019 study published in Nature Communications found that kisspeptin administration restored normal reproductive function in 75% of men with functional hypothalamic hypogonadism. A condition where oxytocin has zero documented th…
Here's the honest answer: there is no 'better' peptide between LL-37 and VIP. They don't compete for the same role. LL-37 is a frontline antimicrobial that operates at barrier surfaces where pathogens first encounter the immune s…
Let's be direct: the comparison only makes sense if you misunderstand what these peptides do. Kisspeptin controls reproductive hormone release at the hypothalamic level. It's the ignition switch for the entire HPG axis. Oxytocin …
Most comparison articles get this wrong from the first sentence: DSIP (Delta Sleep-Inducing Peptide) and Ipamorelin don't occupy the same category. DSIP is a neuromodulatory nonapeptide that influences sleep architecture through …
Here's the honest answer: neither peptide is FDA-approved for human therapeutic use, and both exist in the research-grade space because they didn't cross the efficacy threshold required for drug approval. Not because they're unsa…
Before making a peptide selection for your research protocol, understanding the mechanistic and practical differences between 5-Amino-1MQ and AOD-9604 determines experimental validity and result interpretation. Primary Mechanism …
The clearest way to understand Adamax science explained is through direct comparison to the peptides that preceded it. Receptor Targets GLP-1 receptor only GLP-1 + GIP receptors Dual-receptor activation produces synergistic metab…
SS-31 vs SS-LUP-332: Which Peptide Works Better? SS-31 targets mitochondrial membranes for cardioprotection, while SS-LUP-332 activates ERRγ for metabolic enhancement — each serves distinct research A 2022 Phase 3 trial published…
DSIP (delta sleep-inducing peptide) 30–60 minutes Increases slow-wave sleep (stages 3–4) by 20–30%; preserves REM cycles; no suppression of natural sleep stages None observed after 12 weeks nightly use Minimal to none. Reaction t…
Ischaemia-reperfusion injury Reduces infarct size 15–25%, prevents cytochrome c release, maintains ATP production during reperfusion No protective effect. Insufficient time for transcriptional changes Hours SS-31 is the only viab…
| Compound Class | Primary Mechanism | Slow-Wave Sleep Impact | REM Sleep Impact | Tolerance Development | Cortisol Suppression | Professional Assessment ||—|—|—|—|—|—|| DSIP (Delta Sleep-Inducing Peptide) | GABAergic modulation …
SS-31's active sequence (D-Arg-Dmt-Lys-Phe-NH₂) carries alternating positive charges that electrostatically bind cardiolipin, a phospholipid enriched 1000-fold in the inner mitochondrial membrane compared to other cellular membra…
A 2022 Phase 3 trial published in Circulation found SS-31 (elamipretide) reduced mitochondrial dysfunction markers by 37% in heart failure patients after 12 weeks. Yet the compound failed primary endpoints for clinical improvemen…
Here's the honest assessment: neither peptide has delivered on early translational promises. SS-31 reached Phase 3 clinical trials based on compelling preclinical data showing cardioprotection, neuroprotection, and mitochondrial …
SS-31 demonstrates efficacy in ischaemia-reperfusion models where mitochondrial damage occurs within minutes to hours. Myocardial infarction, stroke, transplant organ preservation, acute kidney injury. The EMBRACE STEMI trial (20…